AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26038709 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T > 0.05 ng/mL
Number of subjects: 0
Study 26038709 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 0
Study 26040252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care using QoR9, VAS, surgery-specific questions, and surgical site photos submitted daily for the first 2 weeks and weekly for the following 2 weeks.
Number of subjects: 72
Study 26040252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Number of subjects: 72
Study 26040252 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up care
Number of subjects: 72
Study 26040491 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) preoperative, intraoperative, postoperative
Number of subjects: 54
Study 26040491 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) preoperative, postoperative
Number of subjects: 54
Study 26040491 — intervention group
Group type: COMPARATOR
Intervention: Sham control (preoperative and postoperative placement of needles without skin penetration)
Number of subjects: 54
Study 26040622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (6 mg/m² per day for 5 days every 21 days)
Number of subjects: 41
Study 26040622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 41
Study 26040640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model of human metabolism
Number of subjects: 140
Study 26040640 — intervention group
Group type: COMPARATOR
Intervention: DLW/DXA method
Number of subjects: 140
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods with inorganic phosphates
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods without inorganic phosphates
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereals/grains with inorganic phosphates
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <30
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR 30-44
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR 45-60
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <18.5
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥35-39
Number of subjects: 7895
Study 26040641 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥40
Number of subjects: 7895
Study 26040709 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic Reversal Learning (PRL)
Number of subjects: 53
Study 26040709 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial Reaction Time (SRT)
Number of subjects: 53
Study 26040709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 53
Study 26040806 — intervention group
Group type: EXPERIMENTAL
Intervention: In-stent neoatherosclerosis (NA)
Number of subjects: 88
Study 26040806 — intervention group
Group type: COMPARATOR
Intervention: No NA
Number of subjects: 88
Study 26041100 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG parameters before stenting
Number of subjects: 218
Study 26041100 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-induced platelet-fibrin clot strength (MA)
Number of subjects: 218
Study 26041651 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenarcheal DHEAS
Number of subjects: 177
Study 26041651 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenarcheal SHBG
Number of subjects: 177
Study 26041651 — intervention group
Group type: COMPARATOR
Intervention: Postmenarcheal DHEAS
Number of subjects: 177
Study 26041651 — intervention group
Group type: COMPARATOR
Intervention: Postmenarcheal SHBG
Number of subjects: 177
Study 26041651 — intervention group
Group type: COMPARATOR
Intervention: Estrogens, progesterone, androstenedione, testosterone (pre- or postmenarche)
Number of subjects: 177
Study 26041675 — intervention group
Group type: EXPERIMENTAL
Intervention: Term milk
Number of subjects: 28
Study 26041675 — intervention group
Group type: COMPARATOR
Intervention: Preterm milk
Number of subjects: 28
Study 26041763 — intervention group
Group type: EXPERIMENTAL
Intervention: Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity
Number of subjects: 24
Study 26042486 — intervention group
Group type: EXPERIMENTAL
Intervention: IV oseltamivir 2-3 mg/kg (age<1 year) or 2.5-3 mg/kg (max. 100 mg; age 1-12 years) by slow IV infusion twice daily for up to 6 days
Number of subjects: 17
Study 26042486 — intervention group
Group type: EXPERIMENTAL
Intervention: IV oseltamivir
Number of subjects: 17
Study 26043810 — intervention group
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa 30-60U/kg by intravenous infusion every other week
Number of subjects: 24
Study 26043810 — intervention group
Group type: COMPARATOR
Intervention: imiglucerase ERT
Number of subjects: 24
Study 26043810 — intervention group
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Number of subjects: 24
Study 26044314 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD subjects (IBD-I and IBD-N)
Number of subjects: 270
Study 26044314 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD) subjects
Number of subjects: 270
Study 26044314 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV presence
Number of subjects: 270
Study 26044314 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 270
Study 26044316 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic sphincter augmentation device
Number of subjects: 100
Study 26044317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Daclatasvir (n = 15)
Number of subjects: 23
Study 26044317 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir and Ribavirin (n = 8)
Number of subjects: 23
Study 26045135 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte-derived hepatocyte-like (MH) cells
Number of subjects: 54
Study 26045135 — intervention group
Group type: COMPARATOR
Intervention: RUCAM scoring system
Number of subjects: 54
Study 26045305 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra transcatheter pacing system
Number of subjects: 140
Study 26046014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level, stepped behavioral intervention
Number of subjects: 527
Study 26046014 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 527
Study 26046067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of Clostridium novyi-NT spores
Number of subjects: 1
Study 26046412 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 10
Study 26046448 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (CRS with nasal polyps and bronchial asthma)
Number of subjects: 90
Study 26046448 — intervention group
Group type: COMPARATOR
Intervention: Group I (CRS without nasal polyps or bronchial asthma)
Number of subjects: 90
Study 26046448 — intervention group
Group type: COMPARATOR
Intervention: Group II (CRS with nasal polyps but without bronchial asthma)
Number of subjects: 90
Study 26047468 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Functional Electrical Stimulation (AFES) applied for 20-40 minutes per day, five times per week for four weeks
Number of subjects: 10
Study 26047468 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilator dependent tetraplegic participants matched based on injury level, age, and sex)
Number of subjects: 10
Study 26048034 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 3 (patients with at least one variant allowing lysosomal localization of mutant MAN2B1)
Number of subjects: 66
Study 26048034 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 3
Number of subjects: 66
Study 26048034 — intervention group
Group type: COMPARATOR
Intervention: Subgroup 2 and/or subgroup 1 (with no lysosomal localization of mutant MAN2B1)
Number of subjects: 66
Study 26048203 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli HU2117 (pre-coated study catheters)
Number of subjects: 10
Study 26048252 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary sclerosing cholangitis
Number of subjects: 60
Study 26048252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease
Number of subjects: 60
Study 26048252 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 26048404 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-smokers with COPD (FEV1/FVC<lower limits of normal)
Number of subjects: 5176
Study 26048404 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 5176
Study 26048404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-smokers
Number of subjects: 5176
Study 26048404 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-smokers and ever-smokers
Number of subjects: 5176
Study 26048686 — intervention group
Group type: EXPERIMENTAL
Intervention: High caloric (428 kcal) (13)C-Sodium Octanoate breath test OFF dopaminergic medication
Number of subjects: 37
Study 26048686 — intervention group
Group type: COMPARATOR
Intervention: 100 mg oral Levodopa/25 mg Benserazide
Number of subjects: 37
Study 26048877 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 106
Study 26048877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercarbia
Number of subjects: 106
Study 26048961 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 20
Study 26049121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal catumaxomab infusion
Number of subjects: 6
Study 26049121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro catumaxomab stimulation
Number of subjects: 6
Study 26049121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro experiments with ascites microenvironment
Number of subjects: 6
Study 26049121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro experiments with EpCAM(+) tumour cells
Number of subjects: 6
Study 26049148 — intervention group
Group type: EXPERIMENTAL
Intervention: MS clinical trial datasets
Number of subjects: 1589
Study 26049148 — intervention group
Group type: EXPERIMENTAL
Intervention: ADNI dataset
Number of subjects: 1589
Study 26049686 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab treatment in mCRC patients (exact dosage and duration not specified)
Number of subjects: 3196
Study 26049686 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab treatment in mCRC patients with confirmed WT KRAS exon 2 status
Number of subjects: 3196
Study 26049686 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3196
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg/mL TCI propofol
Number of subjects: 80
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg/mL TCI propofol
Number of subjects: 80
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 μg/mL TCI propofol
Number of subjects: 80
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia Severity Score (DSS)
Number of subjects: 80
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer's Assessment of Alertness/Sedation (OAAS)
Number of subjects: 80
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration and Aspiration Scale (PAS)
Number of subjects: 80
Study 26049781 — intervention group
Group type: EXPERIMENTAL
Intervention: OAAS
Number of subjects: 80
Study 26049896 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa (0.1 to 3.0 mg/kg, intravenously every 2 weeks for 26 weeks)
Number of subjects: 5
Study 26050535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral PMMRI
Number of subjects: 400
Study 26051481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 100
Study 26051481 — intervention group
Group type: EXPERIMENTAL
Intervention: N370S/84GG genotype patients
Number of subjects: 100
Study 26051481 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomised patients
Number of subjects: 100
Study 26053233 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 0
Study 26053233 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 0
Study 26053233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPAP and Surfactant
Number of subjects: 0
Study 26053349 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-oriented approach to measuring parenting style
Number of subjects: 0
Study 26053349 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (income)
Number of subjects: 0
Study 26053349 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting style
Number of subjects: 0
Study 26053349 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between income and parenting style
Number of subjects: 0
Study 26053664 — intervention group
Group type: EXPERIMENTAL
Intervention: TN-depleted PBSC grafts
Number of subjects: 35
Study 26053994 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthetic agents (halogenated agents or propofol)
Number of subjects: 362
Study 26053994 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 362
Study 26054585 — intervention group
Group type: EXPERIMENTAL
Intervention: PDACs (PDA-002)
Number of subjects: 0
Study 26055218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 20
Study 26055218 — intervention group
Group type: COMPARATOR
Intervention: Gla-100
Number of subjects: 20
Study 26055298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus standard tacrolimus/methotrexate after busulfan/fludarabine MAC
Number of subjects: 34
Study 26055298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based MAC HSCT
Number of subjects: 34
Study 26055439 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd-graft-arterial group
Number of subjects: 1419
Study 26056248 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) in patients with CKD
Number of subjects: 8400
Study 26056248 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) in patients without CKD
Number of subjects: 8400
Study 26056248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD without HPR
Number of subjects: 8400
Study 26056248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without CKD and without HPR
Number of subjects: 8400
Study 26056491 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/drospirenone 24/4 regimen
Number of subjects: 594
Study 26056491 — intervention group
Group type: COMPARATOR
Intervention: EE/DSG 21/7 regimen
Number of subjects: 594
Study 26056530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal hypertension (IAH) defined as IAP ≥ 12 mmHg
Number of subjects: 46
Study 26056530 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of intra-abdominal hypertension (IAH)
Number of subjects: 46
Study 26058673 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD) group with abnormal ABI (≤ 0.9)
Number of subjects: 124
Study 26058673 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal ABI (> 0.9)
Number of subjects: 124
Study 26058673 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 124
Study 26058927 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells (MSCs) injection
Number of subjects: 17
Study 26059205 — intervention group
Group type: EXPERIMENTAL
Intervention: PressureEasy® device for continuous control of P cuff for 24 hours
Number of subjects: 18
Study 26059205 — intervention group
Group type: COMPARATOR
Intervention: Routine care using a manometer for discontinuous control of P cuff every 4 hours for 24 hours
Number of subjects: 18
Study 26059238 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally controlled pressure support (PSN)
Number of subjects: 12
Study 26059238 — intervention group
Group type: COMPARATOR
Intervention: Conventional pneumatically-controlled pressure support (PSP)
Number of subjects: 12
Study 26059242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BMDMCs) administered through bronchoscopy (2 × 10(7) cells)
Number of subjects: 5
Study 26059523 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 140
Study 26059540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cripto-1 knockout by the CRISPR-Cas9 system
Number of subjects: 0
Study 26059603 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted echo time optimized PRESS sequence for (1) H-MRS
Number of subjects: 26
Study 26059647 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 33
Study 26059647 — intervention group
Group type: COMPARATOR
Intervention: Boosted Atazanavir (ATV)
Number of subjects: 33
Study 26059839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Disorders Questionnaire (MDQ) added to the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 1279
Study 26059839 — intervention group
Group type: EXPERIMENTAL
Intervention: MDQ with traditional scoring
Number of subjects: 1279
Study 26059839 — intervention group
Group type: EXPERIMENTAL
Intervention: MDQ scored without the impairment criterion
Number of subjects: 1279
Study 26059948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily
Number of subjects: 111
Study 26059979 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial factors assessment
Number of subjects: 1293
Study 26059979 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable regression model with stepwise selection
Number of subjects: 1293
Study 26059979 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stressors
Number of subjects: 1293
Study 26060202 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of G3I
Number of subjects: 572
Study 26060285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-exposed infants
Number of subjects: 143
Study 26060285 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir-unexposed infants
Number of subjects: 143
Study 26060319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectasis exacerbations
Number of subjects: 48
Study 26060319 — intervention group
Group type: COMPARATOR
Intervention: Potentially pathogenic microorganism or P. aeruginosa isolation
Number of subjects: 48
Study 26060513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% applied topically to upper eyelid margins for six months
Number of subjects: 130
Study 26060513 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied topically to upper eyelid margins for six months
Number of subjects: 130
Study 26061561 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy
Number of subjects: 0
Study 26061661 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes
Number of subjects: 959
Study 26061661 — intervention group
Group type: COMPARATOR
Intervention: tobacco smoking
Number of subjects: 959
Study 26061661 — intervention group
Group type: COMPARATOR
Intervention: dual smoking
Number of subjects: 959
Study 26062008 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCU-CHEK(®) Aviva
Number of subjects: 200
Study 26062008 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour(®) XT
Number of subjects: 200
Study 26062008 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoCheck XL
Number of subjects: 200
Study 26062008 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoMen(®) LX PLUS
Number of subjects: 200
Study 26062008 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO 15197-distributed samples
Number of subjects: 200
Study 26062008 — intervention group
Group type: COMPARATOR
Intervention: Comparison methods (glucose oxidase and hexokinase)
Number of subjects: 200
Study 26062135 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure for PTSD with dialectical behavior therapy
Number of subjects: 16
Study 26062610 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal care in Thatta, Pakistan
Number of subjects: 10000
Study 26062714 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Newborn Health Registry (MNHR)
Number of subjects: 0
Study 26062714 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance metrics of data quality monitoring
Number of subjects: 0
Study 26062714 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control program of MNHR
Number of subjects: 0
Study 26062823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a multikinase VEGF inhibitor (pazopanib/Votrient®)
Number of subjects: 1
Study 26062899 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based pregnancy registry study
Number of subjects: 282626
Study 26062899 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher LTFU
Number of subjects: 282626
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: No formal education
Number of subjects: 277736
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary education only
Number of subjects: 277736
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary education only
Number of subjects: 277736
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of antenatal care
Number of subjects: 277736
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section delivery
Number of subjects: 277736
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhage
Number of subjects: 277736
Study 26062992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive disorders
Number of subjects: 277736
Study 26063065 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g tomato puree providing 0.4 mg β-carotene
Number of subjects: 33
Study 26063065 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 25 SNPs in 12 genes
Number of subjects: 33
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin-containing supplements
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental folic acid
Number of subjects: 368
Study 26063067 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin B-12
Number of subjects: 368